Meeting
2020 ASCO Virtual Scientific Program
Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF.
Authors
Roy S. Herbst
Yale University, New Haven, CT
Roy S. Herbst , Hendrik-Tobias Arkenau , Emiliano Calvo , Johanna C. Bendell , Nicolas Penel , Charles S. Fuchs , Samuel McNeely , Erik R Rasmussen , Hong Wang , Joana M Oliveira , David Raymond Ferry , Ian Chau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Inflammatory Signatures
Clinical Trial Registration Number
NCT02443324
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3089)
DOI
10.1200/JCO.2020.38.15_suppl.3089
Abstract #
3089
Poster Bd #
153
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF).
First Author: Ian Chau
Poster
2023 ASCO Annual Meeting
A phase 1 trial of umbilical cord blood–derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non–small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors.
First Author: Miguel Angel Villalona-Calero
Poster
2023 ASCO Annual Meeting
A comprehensive pan-cancer analysis of PD-L1 expression using clone E1L3N in Chinese patients with cancer.
First Author: Huangbin Lu
Poster
2019 ASCO Annual Meeting
Efficacy and safety of pembrolizumab in patients with PD-L1 positive advanced biliary tract cancer (BTC): A prospective cohort study.
First Author: Junho Kang